Showing results (381-390 of 410) with videos related to

Sort By:
Pageof 41
Blood|November 26, 1999
A randomized, double-blind, placebo-controlled study with pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) as an adjunct to chemotherapy for adults with de novo acute myeloid leukemiaE Archimbaud, O G Ottmann, J A Yin, et al.
Vnitrni Lekarstvi|April 17, 2010
[Treatment of adult acute lymphoblastic leukemia according to GMALL 07/2003 study protocol in the Czech Republic - the first experience]F Folber, C Sálek, M Doubek, et al.
British Journal of Haematology|November 25, 2003
Pegylated asparaginase in combination with high-dose methotrexate for consolidation in adult acute lymphoblastic leukaemia in first remission: a pilot studyO Rosen, H J Müller, N Gökbuget, et al.
Leukemia|November 15, 2014
PF-114, a potent and selective inhibitor of native and mutated BCR/ABL is active against Philadelphia chromosome-positive (Ph+) leukemias harboring the T315I mutationA A Mian, A Rafiei, I Haberbosch, et al.
Leukemia|November 21, 2008
Favorable prognostic impact of NPM1 gene mutations in childhood acute myeloid leukemia, with emphasis on cytogenetically normal AMLI H I M Hollink, C M Zwaan, M Zimmermann, et al.
Leukemia|September 16, 1998
High rate of chromosome abnormalities detected by fluorescence in situ hybridization using BCR and ABL probes in adult acute lymphoblastic leukemiaH Rieder, C Bonwetsch, L A Janssen, et al.
European Journal of Cancer (Oxford, England : 1990)|August 15, 2002
Reduced-dose cladribine (2-CdA) plus mitoxantrone is effective in the treatment of mantle-cell and low-grade non-Hodgkin's lymphomaM J Rummel, K U Chow, T Karakas, et al.
Onkologie|July 7, 2001
Treatment of aggressive, or progressing indolent peripheral T- and NK-cell neoplasias by combination of fludarabine, cyclophosphamide and doxorubicineE Weidmann, S Boehrer, K U Chow, et al.
Annals of Hematology|February 9, 2000
Intensive chemotherapy with idarubicin, ara-C, etoposide, and m-AMSA followed by immunotherapy with interleukin-2 for myelodysplastic syndromes and high-risk Acute Myeloid Leukemia (AML)A Ganser, G Heil, G Seipelt, et al.
Leukemia|January 11, 2012
Prevalence and dynamics of bcr-abl kinase domain mutations during imatinib treatment differ in patients with newly diagnosed and recurrent bcr-abl positive acute lymphoblastic leukemiaH Pfeifer, T Lange, S Wystub, et al.
Pageof 41